Skip to content
Subscriber Only

Teva Sees 2013 Sales, Profit Below Analyst Estimates

Teva Pharmaceutical Industries Ltd.’s sales and profit next year will miss analyst forecasts, the company said today as new Chief Executive Officer Jeremy Levin prepares to lay out his strategy for investors next month.

Revenue will be between $19.5 billion and $20.5 billion, and earnings excluding some costs will be $4.85 to $5.15 a share, the Petach Tikva, Israel-based company said in a statement. Analysts predicted $20.8 billion and $5.63, respectively, based on average estimates compiled by Bloomberg.